A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

NCT01121133 | Completed Phase 1

• 1 other identifier: M10-955
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.

Conditions

Lymphoma, Including Chronic Lymphocytic Leukemia; Solid Tumors

Outcome Measures

Primary Outcomes (1)

• To determine the effect of rifampin on the pharmacokinetics of navitoclax.

  Weekly

Secondary Outcomes (1)

• To determine the safety of navitoclax when administered alone and in combination with rifampin in these patients.

  Daily

Study Arms (1)

Arm A (navitoclax and rifampin)

EXPERIMENTAL

Drug: navitoclax; Drug: Rifampin

Interventions

navitoclax DRUG

Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.

Also known as: ABT-263, navitoclax

Arm A (navitoclax and rifampin)

Rifampin DRUG

Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.

Arm A (navitoclax and rifampin)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older.
• Has a non-hematologic malignancy (radiographic, histologic, or cytologic confirmation), or hematologic malignancy (histologic or cytologic confirmation) that is either: relapsed or refractory to standard therapy, failed at least one prior therapy or no known effective therapy exists.
• In the investigator's opinion, the subject's life expectancy is at least 90 days.
• If clinically indicated, (e.g., subjects over the age of 70) subjects must have documented brain imaging (MRI or CT) negative for subdural or epidural hematoma within 28 days prior to the first dose of study drug.

You may not qualify if:

• Subjects with brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the first dose of study drug.
• History of or is clinically suspicious for cancer-related central nervous system (CNS) disease.
• Has undergone an allogeneic stem cell transplant.
• Has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding.
• Has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
• Has active immune thrombocytopenic purpura or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).
• Significant history of cardiovascular disease (e.g., MI, thrombotic or thromboembolic event in the last 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease. Female subject is pregnant or breast-feeding.
• History of or an active medical condition(s) that affects absorption or motility (e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, etc).
• Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
• tuberculosis
• diagnosis of fever and neutropenia within 1 week prior to study drug administration
• Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for hypothyroidism or estrogen replacement therapy \[ERT\], or agonists required to suppress serum testosterone levels \[e.g., LHRH, GnRH, etc.\] for subjects with prostate cancer Subject is currently receiving or requires anticoagulation therapy (e.g., warfarin at any dose) or any drugs or herbal supplements that affect platelet function, with the exception of low-dose heparin used to maintain the patency of a catheter.
• Subject has used known inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin and carbamazepine) of cytochrome P450 3A (CYP3A) within 1 week prior to first dose of study.
• Subject has a history of hypersensitivity to any of the rifamycins.
• In the opinion of the Investigator, the subject is an unsuitable candidate to receive ABT-263.

Sponsors & Collaborators

• AbbVie: lead

Related Publications (1)

• Yang J, Pradhan RS, Rosen LS, Graham AM, Holen KD, Xiong H. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec;39(6):680-4. doi: 10.1111/jcpt.12193. Epub 2014 Jul 22.

  PMID: 25047139 RESULT

MeSH Terms

Conditions

Lymphoma

Interventions

navitoclax; Rifampin

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Rifamycins; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Lactams, Macrocyclic; Macrocyclic Compounds; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: May 10, 2010
• First Posted: May 12, 2010
• Study Start: May 1, 2010
• Primary Completion: May 1, 2011
• Study Completion: May 1, 2011
• Last Updated: November 21, 2017

Record last verified: 2011-05